Summary

for people ages 18 years and up (full criteria)
at Irvine, California and other locations
study started

Description

Summary

The purpose of this program is to provide expanded access to Inotersen for up to 100 Patients with Hereditary Transthyretin Amyloidosis (hTTR).

Official Title

Expanded Access Program for Inotersen (ISIS 420915) in Patients With Hereditary Transthyretin Amyloidosis (hATTR)

Details

The Program is intended to provided expanded access to Inotersen for eligible patients with hATTR who have limited or no available treatment options.

Keywords

Amyloidosis, Hereditary Amyloidosis Amyloidosis, Familial Inotersen

Eligibility

You can join if…

Open to people ages 18 years and up

  • Male or female at least 18 years of age with a diagnosis of hATTR
  • Symptoms consistent with polyneuropathy
  • Meet Polyneuropathy Disability (PND) Stage I-III requirements

You CAN'T join if...

  • Known Primary Amyloidosis, Leptomeningeal Amyloidosis or Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma
  • Have inadequate cardiac function
  • Have low platelet counts
  • Have inadequate renal function

Locations

  • University of California - Irvine
    Irvine California 92697 United States
  • SC3 Research - Pasadena
    Pasadena California 91105 United States

Details

Status
not accepting new patients
Start Date
Sponsor
Ionis Pharmaceuticals, Inc.
ID
NCT03400098
Study Type
Expanded Access
Last Updated